CELL-EASY
Cell-Easy, a start-up based in Toulouse specialized in stem cell therapy, announces today the signature of an agreement with the University Hospital Centre in Toulouse, as well as securing the authorization to open a pharmaceutical manufacturing plant dedicated to the production of stem cells - a first in France. This follows the announcement made last December of raising 1M€ capital investment.
Thanks to its innovative mass scale stem cells manufacturing process, Cell Easy aims to develop regenerative medicine through therapeutic solutions based on Advanced Therapy Medicinal Products compatible with affordable access for millions of patients.
The start-up has now signed a first partnership with the University Hospital Center in Toulouse and will be producing Mesenchymal stem cells (or stromal cells) sourced from qualified fat tissue in accordance with good manufacturing practices. A first clinical trial is on its way to fight against Alzheimer disease.
« Our ambition is to industrialize our proprietary stem cell manufacturing process to make Cell Therapy accessible to the largest number possible of patients. The aim is to cut costs by ten and increase production capacity beyond 100 0000 doses /year. » explains Pierre Monsan, DG of Cell-Easy and Founder of Toulouse White Biotechnology (TWB).
« Today, stem cell-based treatments represent a major therapeutic hope. What has been set up here is very much the expression of the way the University Hospital Centre approaches the development of innovative technologies, therapies and organizations that support new therapies founded on cross fertilization of talent and expertise . » says Marc Penaud, Executive Manager of the University Hospital Center in Toulouse.
Furthermore, the French Medicines Agency, also gave Cell-Easy the authorization to open a pharmaceutical plant to manufacture stem cell batches at large scale, in accordance with GMP (Good Manufacturing Practices) standards. This authorization makes Cell-Easy the only private pharmaceutical organization able to manufacture stem cells in France on an industrial scale. This firmly puts Cell-Easy on the European stage.
Capital investment is being secured to finance the quick implementation of their strategy in France but also in Europe where patients’ needs are high.
Cell-Easy will now be able to manufacture stem cells batches for industrial partners and is one of the world’s precursors in cell therapy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005563/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ClickHouse Acquires LibreChat to Democratize AI-Driven Analytics Through the Open-Source Agentic Data Stack4.11.2025 18:00:00 CET | Press release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytics database, today announced the acquisition of LibreChat, a leading open-source AI chat platform that provides a unified interface for interacting with large language models (LLMs). The acquisition brings LibreChat founder Danny Avila and his team to ClickHouse. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104505230/en/ ClickHouse acquires LibreChat: Introducing the open-source Agentic Data Stack Together, ClickHouse and LibreChat form the foundation of the open-source Agentic Data Stack, empowering teams to deploy AI agents that analyze and act on large datasets through natural language. This shift to agentic analytics is already transforming how organizations such as Shopify, Daimler Truck, Fetch, and cBioPortal leverage their data, demonstrating the immediate value in real-world applications. At Shopify, LibreChat has become c
Mouser Electronics Explores the Future of Advanced Air Mobility and Its Impact on Design4.11.2025 17:37:00 CET | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, released its latest installment of the Empowering Innovation Together (EIT) technology series, Urban Transport Takes Flight, examining the emerging sector of Advanced Air Mobility (AAM). This series details the technology behind electric vertical takeoff and landing (eVTOL) vehicles, the challenges of infrastructure for city deployment, and the hydrogen fuel cell solutions that power the future of urban transport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104083206/en/ Mouser explores the technology behind urban air mobility (UAM) vehicles, the challenges of infrastructure, and the fuel solutions that are powering the future of urban transport. The path for Urban Air Mobility (UAM) to transition from futuristic concept to scalable reality is constrained by barriers in form, power, and
Sparkle Clean Tech and Aquadei Launch Global Alliance to Transform Oil & Gas Water Treatment with Next-Gen Nanobubble Technology4.11.2025 17:02:00 CET | Press release
Sparkle Clean Tech (SCT)(exclusive global licensee of Siemens Energy’s oil & gas water-treatment IP) and Aquadei, LLC have formed a strategic alliance to deploy Aquadei’s proprietary nanobubble and hydrodynamic cavitation technologies to oil & gas operations globally. This partnership is set to drive advanced water treatment methods, delivering measurable operational, economic and environmental benefits across the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104652683/en/ Nanobubble Technology in Oil & Gas: Performance Advantages Nanobubbles (gas particles smaller than 200 nanometers) feature extraordinary physical surface and interfacial properties that enhance how oil and solids interact in water. When paired with SCT’s separation technologies, these ultrafine bubbles enable more efficient separation, lower chemical consumption, and greater process stability. Unlike traditional flotation systems that rely on
GD32 MCU Family Expands High-Performance Portfolio with New GD32F503/505 Series MCU4.11.2025 17:00:00 CET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced the official launch of the GD32F503/505 high-performance series of 32-bit general-purpose microcontrollers. This release significantly strengthens its product portfolio based on the Arm® Cortex®-M33 core. Built on the Arm® v8-M architecture, the series operates at a frequency of 280 MHz and features flexible memory configurations and built-in security functions. It is well-suited for a wide range of applications, including digital power supplies, industrial automation, motor control, robotic vacuum cleaners, BMS, humanoid robots, and more. The GD32F503/505 series MCUs are now available as samples and development boards are available on request, with mass production due to begin in December. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104783233/en/ Higher Frequency for S
Zetagen Therapeutics to Present Promising Preclinical Data at SABCS: Zeta-BC-007 Demonstrates Superior Tumoricidal Activity and Survival Benefit in Breast Cancer Model4.11.2025 16:48:00 CET | Press release
Survival Advantage: Mice treated with Zeta-BC-007 survived beyond 60 days, unlike those receiving Tamoxifen (TAM) or Abemaciclib (ABE)Tumor Reduction: Zeta-BC-007 combinations reduced tumor volume by up to 66%, compared to 34% (TAM) and 15% (ABE)Synergistic Cytotoxicity: NaN and ABE together decreased cell proliferation by 60% in vitro, suggesting synergistic effectsNo Tumor Activity: Histology revealed no ki67 staining and increased necrosis in Zeta-BC-007-treated tumorsImmune Activation: Treated mice showed elevated macrophage infiltration and increased circulating monocytes Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom